SABCS 2023 | Immune-related AEs in patients with breast cancer treated with IO

Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, discusses a real-world study to understand the toxicity of immunotherapy (IO) and immune-related adverse events (irAEs) in patients with breast cancer ≥65 years treated with pembrolizumab or atezolizumab. The aim of this retrospective review was to help inform clinical decision making in this patient population. In this patient cohort, similar overall rates of irAEs were observed in patients ≥65 years and less than 65 years. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.